- Home
- LYT vs BJDX Comparison
LYT vs BJDX Comparison
Compare LYT & BJDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LYT
- BJDX
- Stock Information
- Founded
- LYT 2020
- BJDX 2015
- Country
- LYT India
- BJDX United States
- Employees
- LYT N/A
- BJDX N/A
- Industry
- LYT EDP Services
- BJDX Medical Specialities
- Sector
- LYT Technology
- BJDX Health Care
- Exchange
- LYT Nasdaq
- BJDX Nasdaq
- Market Cap
- LYT 1.8M
- BJDX 1.8M
- IPO Year
- LYT 2022
- BJDX 2021
- Fundamental
- Price
- LYT $0.72
- BJDX $3.35
- Analyst Decision
- LYT
- BJDX
- Analyst Count
- LYT 0
- BJDX 0
- Target Price
- LYT N/A
- BJDX N/A
- AVG Volume (30 Days)
- LYT 4.4M
- BJDX 149.2K
- Earning Date
- LYT 08-15-2024
- BJDX 11-07-2024
- Dividend Yield
- LYT N/A
- BJDX N/A
- EPS Growth
- LYT N/A
- BJDX N/A
- EPS
- LYT 0.30
- BJDX N/A
- Revenue
- LYT $21,363,775.00
- BJDX N/A
- Revenue This Year
- LYT N/A
- BJDX N/A
- Revenue Next Year
- LYT N/A
- BJDX N/A
- P/E Ratio
- LYT $2.42
- BJDX N/A
- Revenue Growth
- LYT 12.39
- BJDX N/A
- 52 Week Low
- LYT $0.54
- BJDX $3.03
- 52 Week High
- LYT $18.62
- BJDX $388.00
- Technical
- Relative Strength Index (RSI)
- LYT 30.59
- BJDX 42.75
- Support Level
- LYT $0.54
- BJDX $3.30
- Resistance Level
- LYT $0.76
- BJDX $3.67
- Average True Range (ATR)
- LYT 0.08
- BJDX 0.37
- MACD
- LYT 0.01
- BJDX -0.05
- Stochastic Oscillator
- LYT 40.91
- BJDX 2.94
About LYT Lytus Technologies Holdings PTV. Ltd.
Lytus Technologies Holdings Pvt Ltd is a platform services company providing content streaming/telecasting services to users located all across India. Its scope of business also covers telemedicine services with local assistance through local Health Centers. Through its platform, the customers are well connected via customer premises equipment (CPE) devices/set-top boxes (STBs) and have access to multi-dimensional services including telemedicine service.
About BJDX Bluejay Diagnostics Inc.
Bluejay Diagnostics Inc is a medical diagnostics company. It is developing rapid tests using whole blood using its Symphony technology platform to improve patient outcomes in critical care settings. The company's first product, the Symphony IL-6 test, is for the monitoring of disease progression in critical care settings and is a clinically established inflammatory biomarker for the assessment of the severity of infection and inflammation across many disease indications, including sepsis.